

ELENCO PUBBLICAZIONI

- Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, De Nicola S, Cheroni C, **Grassi E**, Colombo M. **Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients.** Biomed Res Int. 2013;2013:580796. doi: 10.1155/2013/580796.
- **Grassi E**, Aghemo A. **How to optimize HCV therapy in genotype 2 patients.** Liver Int. 2013 Feb;33 Suppl 1:35-40. doi: 10.1111/liv.12056.
- Aghemo A, **Grassi E**, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M. **Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.** PLoS One. 2014 Apr 23;9(4):e95881.
- Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrilu C, Aghemo A, Di Paolo D, Squadrito G, **Grassi E**, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators. **An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.** Dig Liver Dis. 2014 Sep;46(9):818-25.
- D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, **Grassi E**, Casazza G, Rosenberg W, Bedossa P, Colombo M. **Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.** PLoS One. 2016 Jun 15;11(6):e0155967.